The enduring continuum of multiple sclerosis (MS) involves careful evaluation of the clinical course before and after the initiation of therapy. Whereas many neurologists accept a conventional treatment approach, patients often progress with a risk of accruing irreversible disability. Timely monitoring and sequencing to high-efficacy disease-modifying therapies (DMTs), accompanied by proper patient counseling, can benefit in managing the disease in the long-term. Let’s hear the expert opinions on options and current strategies for real-world considerations of high-efficacy DMTs in MS.
Sanofi has organized an International Speaker Program Live from Sofitel Hotel, BKC, Mumbai on 27 th July 2019, 08.00 PM onwards. In this International Speaker Program , experts will discuss Real-World Considerations For High-Efficacy DMTs In MS: Options And Current Strategies. The agenda of the…
